{"id":"https://openalex.org/W3027280232","doi":"https://doi.org/10.17638/03076608","title":"THE PHARMACOKINETICS, PHARMACODYNAMICS AND PHARMACOGENETICS OF DOLUTEGRAVIR AND COBICISTAT IN THE TREATMENT OF HIV","display_name":"THE PHARMACOKINETICS, PHARMACODYNAMICS AND PHARMACOGENETICS OF DOLUTEGRAVIR AND COBICISTAT IN THE TREATMENT OF HIV","publication_year":2020,"publication_date":"2020-01-01","ids":{"openalex":"https://openalex.org/W3027280232","doi":"https://doi.org/10.17638/03076608","mag":"3027280232"},"language":"en","primary_location":{"id":"doi:10.17638/03076608","doi":"https://doi.org/10.17638/03076608","is_oa":true,"landing_page_url":"https://doi.org/10.17638/03076608","pdf_url":null,"source":{"id":"https://openalex.org/S7407050768","display_name":"University of Liverpool","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I146655781","host_organization_name":"University of Liverpool","host_organization_lineage":["https://openalex.org/I146655781"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"article-journal"},"volume":null,"type":"dissertation","is_traditional":true,"indexed_in":["datacite"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://doi.org/10.17638/03076608","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5011969265","display_name":"Emilie R Elliot","orcid":"https://orcid.org/0000-0001-7736-9883","observed_orcids":["https://orcid.org/0000-0001-7736-9883"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Elliot, Emilie","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5011969265"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10082","display_name":"HIV/AIDS Research and Interventions","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/dolutegravir","display_name":"dolutegravir","score":0.9520000219345093},{"id":"https://openalex.org/keywords/cobicistat","display_name":"cobicistat","score":0.9959999918937683},{"id":"https://openalex.org/keywords/hiv-treatment","display_name":"HIV treatment","score":0.7289999723434448},{"id":"https://openalex.org/keywords/integrase-inhibitors","display_name":"integrase inhibitors","score":0.9190000295639038},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9010000228881836},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.9559999704360962},{"id":"https://openalex.org/keywords/pharmacogenetics","display_name":"pharmacogenetics","score":0.9919999837875366},{"id":"https://openalex.org/keywords/older-people-living-with-hiv","display_name":"older people living with HIV","score":0.8809999823570251},{"id":"https://openalex.org/keywords/treatment-adherence","display_name":"medication adherence","score":0.628000020980835},{"id":"https://openalex.org/keywords/elvitegravir","display_name":"elvitegravir","score":0.7099999785423279},{"id":"https://openalex.org/keywords/atazanavir","display_name":"atazanavir","score":0.9200000166893005},{"id":"https://openalex.org/keywords/darunavir","display_name":"darunavir","score":0.9990000128746033},{"id":"https://openalex.org/keywords/drug-interactions","display_name":"drug interactions","score":0.5460000038146973}],"concepts":[{"id":"https://openalex.org/C2779502633","wikidata":"https://www.wikidata.org/wiki/Q937224","display_name":"Dolutegravir","level":5,"score":0.9699532389640808},{"id":"https://openalex.org/C2780524789","wikidata":"https://www.wikidata.org/wiki/Q5138908","display_name":"Cobicistat","level":5,"score":0.9231007099151611},{"id":"https://openalex.org/C2777068322","wikidata":"https://www.wikidata.org/wiki/Q2740966","display_name":"Elvitegravir","level":5,"score":0.8387241363525391},{"id":"https://openalex.org/C2778414717","wikidata":"https://www.wikidata.org/wiki/Q423467","display_name":"Atazanavir","level":5,"score":0.7327011227607727},{"id":"https://openalex.org/C2779298103","wikidata":"https://www.wikidata.org/wiki/Q422618","display_name":"Ritonavir","level":5,"score":0.669999361038208},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6623858213424683},{"id":"https://openalex.org/C22979827","wikidata":"https://www.wikidata.org/wiki/Q5137311","display_name":"Cmax","level":3,"score":0.5709867477416992},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5671234726905823},{"id":"https://openalex.org/C2779182219","wikidata":"https://www.wikidata.org/wiki/Q3765251","display_name":"Darunavir","level":5,"score":0.5573143362998962},{"id":"https://openalex.org/C2780404665","wikidata":"https://www.wikidata.org/wiki/Q421552","display_name":"Raltegravir","level":5,"score":0.4968462288379669},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.48430243134498596},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.4815140664577484},{"id":"https://openalex.org/C14430832","wikidata":"https://www.wikidata.org/wiki/Q412550","display_name":"Integrase","level":3,"score":0.4704902172088623},{"id":"https://openalex.org/C2911190787","wikidata":"https://www.wikidata.org/wiki/Q22075912","display_name":"Tenofovir alafenamide","level":5,"score":0.43219608068466187},{"id":"https://openalex.org/C3013748606","wikidata":"https://www.wikidata.org/wiki/Q15787","display_name":"Human immunodeficiency virus (HIV)","level":2,"score":0.3242414593696594},{"id":"https://openalex.org/C142462285","wikidata":"https://www.wikidata.org/wiki/Q2528140","display_name":"Viral load","level":3,"score":0.2814459204673767},{"id":"https://openalex.org/C159047783","wikidata":"https://www.wikidata.org/wiki/Q7215","display_name":"Virology","level":1,"score":0.19684717059135437},{"id":"https://openalex.org/C2993143319","wikidata":"https://www.wikidata.org/wiki/Q583050","display_name":"Antiretroviral therapy","level":4,"score":0.19428181648254395}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.17638/03076608","doi":"https://doi.org/10.17638/03076608","is_oa":true,"landing_page_url":"https://doi.org/10.17638/03076608","pdf_url":null,"source":{"id":"https://openalex.org/S7407050768","display_name":"University of Liverpool","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I146655781","host_organization_name":"University of Liverpool","host_organization_lineage":["https://openalex.org/I146655781"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"article-journal"},{"id":"mag:3027280232","doi":null,"is_oa":false,"landing_page_url":"https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.803894","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null}],"best_oa_location":{"id":"doi:10.17638/03076608","doi":"https://doi.org/10.17638/03076608","is_oa":true,"landing_page_url":"https://doi.org/10.17638/03076608","pdf_url":null,"source":{"id":"https://openalex.org/S7407050768","display_name":"University of Liverpool","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I146655781","host_organization_name":"University of Liverpool","host_organization_lineage":["https://openalex.org/I146655781"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"article-journal"},"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2894846477","https://openalex.org/W3150840516","https://openalex.org/W2126563844","https://openalex.org/W2415914350","https://openalex.org/W2919538165","https://openalex.org/W7042195125","https://openalex.org/W4300897909","https://openalex.org/W2593285831","https://openalex.org/W2161992903","https://openalex.org/W2690342936"],"abstract_inverted_index":{"Dolutegravir":[0],"(DTG),":[1],"the":[2,10,17,25,54,68,137,204,214,226,267,287,385,408,429],"second-generation":[3],"Integrase":[4],"Inhibitor":[5],"(InSTI)":[6],"and":[7,35,52,89,142,149,169,184,234,258,294,299,321,337,356,382,388,410,414,420,425,433],"Cobicistat":[8],"(COBI),":[9],"new":[11,61],"pharmacological":[12,138],"booster,":[13],"were":[14,178,343],"approved":[15],"for":[16,32,57,225,313,316,319,323],"treatment":[18],"of":[19,27,60,107,126,140,206,216,221,292,332,338,412,428],"HIV":[20,28,157],"in":[21,46,74,134,144,198,209,229,282,304,350,360,367,384,399,416,442],"2013-14.":[22],"DTG":[23,141,194,222,240,293,333,380,413,443],"changed":[24],"landscape":[26],"therapy,":[29],"raising":[30],"standards":[31],"efficacy,":[33],"safety":[34,411],"genetic":[36,207],"barrier.":[37],"It":[38,92],"is":[39,53,112,431,436],"now":[40],"recommended":[41],"as":[42],"first":[43,227],"line":[44],"therapy":[45,167],"most":[47],"major":[48],"including":[49,152],"universal":[50],"guidelines":[51],"anchor":[55],"drug":[56,97,210,264],"a":[58,78,95,105,199,237,308,357,376],"number":[59],"simplified":[62],"ARV":[63],"strategies.":[64],"Meanwhile,":[65],"COBI":[66,143,415],"offers":[67],"opportunity":[69],"to":[70,83,104,115,131,202,252,260,262,438],"reduce":[71],"pill":[72],"burden":[73],"patients":[75],"who":[76,284],"require":[77],"boosted":[79,326],"protease":[80],"inhibitor,":[81],"thanks":[82],"its":[84],"co-formulation":[85],"with":[86,156,273,327,335,341,363,373,404],"atazanavir":[87],"(ATV)":[88],"darunavir":[90],"(DRV).":[91],"also":[93,344],"has":[94],"lesser":[96],"interaction":[98],"profile":[99],"than":[100],"ritonavir":[101],"(RTV),":[102],"secondary":[103,251],"lack":[106],"enzyme":[108],"induction.":[109],"Licensing":[110],"data":[111,397,430],"often":[113],"limited":[114],"highly":[116],"selected":[117],"study":[118,195,201],"participants":[119],"under":[120],"strict":[121],"trial":[122],"conditions.":[123],"The":[124,218,289,329,396,423],"objectives":[125],"this":[127,400],"thesis":[128,401],"are":[129],"therefore":[130],"address":[132],"gaps":[133],"knowledge":[135],"on":[136,213,407],"behaviour":[139],"important":[145,417],"real-life":[146],"patient":[147,418],"groups":[148,419],"clinical":[150,421,426],"scenarios,":[151],"older":[153],"people":[154],"living":[155],"(PLWH),":[158],"women":[159],"taking":[160],"contraception,":[161],"poorly":[162],"adherent":[163],"patients,":[164],"DTG/DRV/COBI":[165,351],"dual":[166],"candidates":[168],"genetically":[170],"distinct":[171],"populations.":[172],"Five":[173],"intensive":[174,219],"pharmacokinetic":[175],"(PK)":[176],"studies":[177],"carried":[179],"out,":[180],"recruiting":[181],"healthy":[182,305],"volunteers":[183],"PLWH":[185,230],"from":[186,192],"four":[187],"UK-based":[188],"centers.":[189],"Pharmacogenetic":[190],"sampling":[191],"each":[193],"was":[196,223,256,270,301,371,391],"used":[197],"final":[200],"explore":[203],"impact":[205],"variability":[208],"disposition":[211],"genes":[212,390],"PK":[215,220,290,311,330,381],"DTG.":[217],"described":[224],"time":[228],"aged":[231],"60":[232],"years":[233],"over,":[235],"showing":[236,307],"significantly":[238],"higher":[239],"Cmax":[241,268],"(25%)":[242],"versus":[243],"younger":[244],"subjects":[245],"(median":[246],"age":[247],"36yrs).":[248],"Discontinuation":[249],"rate":[250],"neuro-psychiatric":[253],"adverse":[254],"events":[255],"4.6%":[257],"seemed":[259],"relate":[261],"elevated":[263],"concentrations,":[265],"but":[266],"increase":[269],"not":[271],"associated":[272],"measured":[274],"sleep":[275],"or":[276],"cognitive":[277],"changes":[278,349,366],"over":[279],"six":[280],"months":[281],"those":[283],"did":[285],"continue":[286],"drug.":[288],"forgiveness":[291],"COBI-boosted":[295],"elvitegravir":[296],"(EVG),":[297],"ATV":[298,320],"DRV":[300,324],"then":[302],"characterised":[303],"volunteers,":[306],"72-hour":[309],"therapeutic":[310],"tail":[312],"DTG,":[314],"36hrs":[315],"EVG,":[317],"30hrs":[318],"24hrs":[322],"when":[325,353,369,394],"COBI.":[328],"impacts":[331],"co-administration":[334],"DRV/COBI":[336],"ethinylestrodiol/levonogestrel":[339],"(EE/LNG)":[340],"ATV/COBI":[342],"investigated.":[345],"Findings":[346],"showed":[347],"minimal":[348],"concentrations":[352],"administered":[354],"together":[355],"25%":[358],"decrease":[359],"EE":[361],"C24":[362],"no":[364],"significant":[365],"LNG":[368],"EE/LNG":[370],"co-administered":[372],"ATV/COBI.":[374],"Finally,":[375],"pharmacogenetic":[377],"association":[378],"between":[379],"variants":[383],"ABCG2,":[386],"UGT1A1":[387],"NRI1/2":[389],"demonstrated,":[392],"particularly":[393],"combined.":[395],"presented":[398],"provides":[402],"clinicians":[403],"key":[405],"information":[406],"pharmacology":[409],"scenarios.":[422],"significance":[424],"validity":[427],"discussed":[432],"an":[434],"argument":[435],"made":[437],"support":[439],"future":[440],"research":[441],"dose":[444],"optimisation.":[445]},"counts_by_year":[],"updated_date":"2026-11-03T10:50:19.383937","created_date":"2020-05-29T00:00:00"}